Physician profile
Meghan J Mallett
NPI 1295193191
$25,227.33
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $33.00 · 2023: $212 · 2024: $7,055 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $730 · Travel and Lodging: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,907.29 |
| Food and Beverage | $730.30 |
| Travel and Lodging | $385.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $24,351.35 | 2024-2025 | Omnipod, Omnipod |
| Abbott Laboratories | $123.10 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Lilly USA, LLC | $112.91 | 2021-2025 | Zepbound, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $101.17 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $100.68 | 2022-2024 | |
| Novo Nordisk INC | $82.24 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.94 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $74.67 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $52.56 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $34.16 | 2024 | Repatha, Otezla |
| Abbvie INC. | $31.43 | 2023 | |
| Astellas Pharma US INC | $25.19 | 2024 | Veozah |
| Exact Sciences Corporation | $15.59 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $15.08 | 2024 | Immunocap |
| Tactile Systems Technology INC | $13.39 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $12.87 | 2023 | Nexlizet, Nexletol, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Mallett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.